4Hassan BA, Yusoff ZB. Negative impact of chemotherapy on breast cancer patients QOL-utility of antiemetic treatment guidelines and the role of race[ J ]. Asian Pac J Cancer Prey,2010,11 (6) : 1523 - 1527.
5Fernandez-Ortega P, Caloto MT, Caloto MT, Chirveches E, et al. Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients' quality of life[ J/OL]. Support Care Cancer,2012 [ 2012-07-16 ]. http://www, ncbi. nlm. nih. gov/ pubmed/22460057.
6Geling O, Eichler HG. Should 5-hyroxytryptamine-3 receptor antagonists be administered beyond 24 hours "after chemotherapy to prevent delayed mesis? Systematic re-evaluation of clinical evidence and drug cost implications[ J]. J Clin Oncol, 2005,23(6) :1289 - 1294.
7Botrel TE, Clark OA, Clark L, et al. Efficacy of palonosetron (PAL) compared to other serotonin inhibitors ( 5-HT ( 3 ) R ) in preventing chemotherapy-induced nausea and vomiting(CINV) in patients receiving moderately or highly emetogenic(MoHE) treatment: systematic review and meta-analysis [ J ]. Support Care Cancer,2011,19 ( 6 ) :823 - 832.
8Zhou LK,Jing X,Ba Y, et al. A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults[ J ]. Oncologist, 2011, 16(2) :207 -216.
9Aogi K, Sakai H, Yoshizawa H, et al. A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy [ J]. Support Care Cancer, 2012,20 (7) : 1507 - 1514.
10Maemondo M, Masnda N, Sekine I, et al. A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy [ J ]. Ann Onco1,2009,20( 11 ) : 1860 - 1866.
